The Satellite Symposium, titled “The data behind your treatment selection in CLL & indolent lymphomas,” provided insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The experts discussed their rationale behind treatment selection, illustrated by case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) were also presented.

The slides are available for download here.